Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs

被引：64

作者：

Hadighi, R. ^{[1
]}

Boucher, P.

Khamesipour, A.

Meamar, A. R.

Roy, G.

Ouellette, M.

Mohebali, M.

机构：

[1] Iran Univ Med Sci, Fac Med, Dept Parasitol, Tehran 14496, Iran

[2] Univ Laval, Ctr Rech Infectiol, Dept Med Biol, Quebec City, PQ G1K 7P4, Canada

[3] Univ Tehran Sci Med, Ctr Res Training Skin Dis & Leprosy, Tehran 14174, Iran

[4] Univ Tehran Sci Med, Sch Publ Hlth, Publ Hlth Res Inst, Tehran 14174, Iran

来源：

PARASITOLOGY RESEARCH | 2007年 / 101卷 / 05期

基金：

加拿大健康研究院;

关键词：

D O I：

10.1007/s00436-007-0638-0

中图分类号：

R38 [医学寄生虫学]; Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ; 100103 ;

摘要：

Cutaneous leishmaniasis (CL) is a major health problem in endemic areas of Iran. The pentavalent antimony (SbV) based drug Glucantime is the first line of treatment for CL in Iran, but recently SbV-resistant Leishmania tropica isolates derived from unresponsive patients were reported. We show in this study that these resistant parasites are cross-resistant to the other SbV-containing drug Pentostam and at least for one isolate also to amphotericin B. However, these resistant isolates were shown to be sensitive to miltefosine and paromomycin. The latter two drugs could thus be useful alternatives for the treatment of leishmaniasis in Iran even for SbV-resistant isolates.

引用

页码：1319 / 1322

页数：4